Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT05004259Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in autoimmune hemolytic anemia (AIHA), sponsored by Dartmouth Health. Primary endpoints: Safety of treatment at 10 weeks and Dose-limiting toxicities at 6 weeks. Started Mar 2022; status: completed.
02
Drugs
daratumumab
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT05004259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004259.